Fulvestrant injection Clinical Trials
8 recruitingDrug
Phase 26Phase 14Phase 32
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Advanced Unresectable or Metastatic Breast Cancer of Adults
Shandong Suncadia Medicine Co., Ltd.180 enrolled2 locationsNCT07389733
Recruiting
Phase 1Phase 2
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Breast CancerOvarian CancerCervical Cancer+5 more
Terremoto Biosciences Inc.205 enrolled15 locationsNCT07109726
Recruiting
Phase 3
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Metastatic Breast CancerLocally Advanced Breast Cancer
Shandong Suncadia Medicine Co., Ltd.240 enrolled2 locationsNCT07024173
Recruiting
Phase 3
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 1Phase 2
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Advanced Solid Tumors
Risen (Suzhou) Pharma Tech Co., Ltd.306 enrolled1 locationNCT06208410
Recruiting
Phase 2
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
GBG Forschungs GmbH120 enrolled25 locationsNCT06607757
Recruiting
Phase 2
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
HER2-negative Breast CancerER+ Breast Cancer
Royal Marsden NHS Foundation Trust1,100 enrolled49 locationsNCT04985266
Recruiting
Phase 1Phase 2
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Metastatic Breast CancerRecurrent Breast CancerAdvanced Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.154 enrolled2 locationsNCT06202261